Patents by Inventor Henry B. Lowman

Henry B. Lowman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOGLOBULIN VARIANTS AND USES THEREOF
    Publication number: 20090155257
    Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
    Type: Application
    Filed: October 22, 2008
    Publication date: June 18, 2009
    Applicant: GENENTECH, INC.
    Inventors: CAMELLIA W. ADAMS, ANDREW C. CHAN, CRAIG W. CROWLEY, HENRY B. LOWMAN, GERALD R. NAKAMURA, LEONARD G. PRESTA
  • METHOD FOR TREATING CARTILAGE DISORDERS
    Publication number: 20090011988
    Abstract: The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.
    Type: Application
    Filed: October 30, 2007
    Publication date: January 8, 2009
    Inventors: Yvonne Man-Yee Chen, Ross G. Clark, Andrea G. Cochran, Yves Dubaquie, Paul J. Fielder, Ellen Filvaroff, Henry B. Lowman, Deborah L. Mortensen, Iain C.A.F. Robinson, Nicholas J. Skelton
  • ANTIBODY VARIANTS
    Publication number: 20090010925
    Abstract: Antibody variants of parent antibodies are disclosed which have one or more amino acids inserted in a hypervariable region of the parent antibody and a binding affinity for a target antigen which is at least about two fold stronger than the binding affinity of the parent antibody for the antigen.
    Type: Application
    Filed: September 28, 2006
    Publication date: January 8, 2009
    Inventors: Yvonne M. Chen, Henry B. Lowman, Yves Muller
  • Antibody Variants with Faster Antigen Association Rates
    Publication number: 20080299115
    Abstract: Antibody variants with faster antigen association rates are disclosed. The antibody variants have one or more amino acid alteration(s) in or adjacent to at least one hypervariable region thereof which increase charge complementarity between the antibody variant and an antigen to which it binds.
    Type: Application
    Filed: April 2, 2008
    Publication date: December 4, 2008
    Inventors: Henry B. Lowman, Jonathan S. Marvin
  • Anti-HER2 antibody variants
    Patent number: 7435797
    Abstract: The present invention concerns novel antibody variants, particularly anti-HER2 antibody variants having substitutions at positions within the variable domains of the heavy and light chains
    Type: Grant
    Filed: April 9, 2003
    Date of Patent: October 14, 2008
    Assignee: Genentech, Inc.
    Inventors: Henry B. Lowman, Resi B. Gerstner, Paul J. Carter
  • Method of inhibiting insulin-like growth factor-1 (IGF-1) by IGF-1-antagonist peptides
    Patent number: 7432244
    Abstract: Peptides are provided that antagonize the interaction of IGF-1 with its binding proteins, insulin receptor, and IGF receptor. These IGF antagonist peptides are useful in treating disorders involving IGF-1 as a causative agent, such as, for example, various cancers.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: October 7, 2008
    Assignee: Genentech, Inc.
    Inventors: Kurt D. Deshayes, Henry B. Lowman, Michelle L. Schaffer, Sachdev S. Sidhu
  • ANTI-VEGF ANTIBODIES
    Publication number: 20080226629
    Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
    Type: Application
    Filed: March 27, 2008
    Publication date: September 18, 2008
    Applicant: Genentech, Inc.
    Inventors: Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-yee Chen
  • Method for treating cartilage disorders
    Patent number: 7423017
    Abstract: The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: September 9, 2008
    Assignee: Genentech, Inc.
    Inventors: Yvonne Man-Yee Chen, Ross G. Clark, Andrea G. Cochran, Yves Dubaquie, Paul J. Fielder, Ellen Filvaroff, Henry B. Lowman, Deborah L. Mortensen, Iain C. A. F. Robinson, Nicholas J. Skelton
  • ANTI-VEGF ANTIBODIES
    Publication number: 20080187534
    Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
    Type: Application
    Filed: January 28, 2008
    Publication date: August 7, 2008
    Applicant: Genentech, Inc.
    Inventors: Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-Yee Chen
  • Polypeptides That Bind Br3 and Uses Thereof
    Publication number: 20080181888
    Abstract: The present invention relates to novel BR3 binding antibodies and polypeptides, including antagonist and agonist polypeptides. The present invention also relates to the use of the BR3 binding antibodies and polypeptides in, e.g., methods of treatment, screening methods, diagnostic methods, assays and protein purification methods.
    Type: Application
    Filed: December 23, 2005
    Publication date: July 31, 2008
    Inventors: Christine M. Ambrose, Mercedesz Balazs, Laura DeForge, Mark S. Dennis, Germaine Fuh, Stephen D. Hurst, Chingwei V. Lee, Henry B. Lowman, Flavius Martin, Gerald R. Nakamura, Dhaya Seshasayee, Melissa Starovasnik, Jeffrey S. Thompson
  • Humanized Anti-Factor D Antibodies and Uses Thereof
    Publication number: 20080118506
    Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Application
    Filed: October 31, 2007
    Publication date: May 22, 2008
    Applicant: Genentech, Inc.
    Inventors: Ling-Ling An, Sek Chung Fung, Robert F. Kelley, Henry B. Lowman, Sanjaya Singh, Herren Wu
  • Anti-VEGF antibodies
    Patent number: 7375193
    Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: May 20, 2008
    Assignee: Genentech, Inc.
    Inventors: Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-Yee Chen
  • Anti-VEGF antibodies
    Patent number: 7365166
    Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: April 29, 2008
    Assignee: Genentech, Inc.
    Inventors: Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-Yee Chen
  • Anti-vegf antibodies
    Patent number: 7297334
    Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
    Type: Grant
    Filed: October 26, 2004
    Date of Patent: November 20, 2007
    Assignee: Genentech, Inc.
    Inventors: Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-yee Chen
  • Anti-VEGF antibodies
    Patent number: 7169901
    Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
    Type: Grant
    Filed: September 3, 2002
    Date of Patent: January 30, 2007
    Assignee: Genentech, Inc.
    Inventors: Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-yee Chen
  • Method for treating IgE-mediated disorders
    Patent number: 7157085
    Abstract: The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of subtituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.
    Type: Grant
    Filed: March 2, 2004
    Date of Patent: January 2, 2007
    Assignee: Genentech, Inc.
    Inventors: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe
  • Methods for treating clinical manifestations of GH/GF axis dysregulation by administration of an IGF-I variant
    Patent number: 7105167
    Abstract: IGF-I variants having an alanine, glycine, or serine amino acid residue at position 16, 25, 49 or at positions 3 and 49 of native-sequence IGF-I are provided that are useful to treat a disorder characterized by dysregulation of the GH/IGF axis in a mammal, such as a renal disorder.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: September 12, 2006
    Assignee: Genentech, Inc.
    Inventors: Yves Dubaquie, Paul J. Fielder, Henry B. Lowman, Deborah L. Mortensen
  • IgE receptor antagonists
    Patent number: 7101851
    Abstract: The invention provides novel compounds which bind to the high affinity receptor for immunoglobulin E (IgE) designated Fc?RI and methods for identifying and preparing such compounds. In particular aspects, the invention provides to the treatment of disorders mediated by IgE utilizing the novel compounds of the invention. The invention also provides composition, such as pharmaceutical compositions, comprising the novel compounds, as well as for their use in research, diagnostic, therapeutic, and prophylactic methods.
    Type: Grant
    Filed: September 26, 2001
    Date of Patent: September 5, 2006
    Assignee: Genentech, Inc.
    Inventors: Henry B. Lowman, Gerald R. Nakamura, Mark E. Reynolds, Melissa A. Starovasnik
  • IGF antagonist peptides
    Patent number: 7071300
    Abstract: Peptides are provided that antagonize the interaction of IGF-1 with its binding proteins, insulin receptor, and IGF receptor. These IGF antagonist peptides are useful in treating disorders involving IGF-1 as a causative agent, such as, for example, various cancers.
    Type: Grant
    Filed: March 13, 2002
    Date of Patent: July 4, 2006
    Assignee: Genentech, Inc.
    Inventors: Kurt D. Deshayes, Henry B. Lowman, Michelle L. Schaffer, Sachdev S. Sidhu
  • Anti-VEGF antibodies
    Patent number: 7060269
    Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: June 13, 2006
    Assignee: Genentech, Inc.
    Inventors: Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-yee Chen